The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Euglycemic hyperinsulinemic clamp to assess insulin sensitivity in vivo

euglycemic hyperinsulinemic clamp

Gold-standard method for assessing drug compound efficacy on whole-body insulin sensitivity.

key benefits

  • Sensitivity (15%) sufficient to detect a statistically significant impact of your compound on insulin resistance.
  • Essential and robust data for your records: the isotopic glucose enrichment procedure is a unique solution giving access to hepatic glucose production, glycolysis and glycogen synthesis.
  • Specific mechanisms targeted by your compound: the insulin dose is chosen to prioritize either hepatic glucose production or peripheral glucose utilization.

Description and parameters

A gold-stantard method to assess insulin sensitivity in vivo

The hyperinsulinemic euglycemic clamp using radioactive labeled tracers is a unique solution for distinguishing your compound from your competitors’ products.

Clamp options

  • Two-step euglycemic hyperinsulinemic clamp:

Provides a global picture of hepatic and peripheral insulin resistance in a single animal: offers an integrated evaluation of mechanisms which are not animal-dependent, saving animals, time, and money.

  • Hyperglycemic hyperinsulinemic clamp:

Provides unique whole body data on insulin-regulated hepatic glycogen synthesis: this technique places the focus on hepatic glycogen synthesis, which is strongly stimulated in hyperglycemic conditions.

Species

  • Rat
  • Mouse

Parameters evaluated

  • Whole-body glucose utilization rate (TO)
  • Hepatic glucose production (HGP)
  • Glucose infusion rate (GIR)
  • Whole-body glycolysis rate.
  • Whole-body glycogen synthesis rate

Add-on studies

  • Individual tissue glucose uptake assay for identifying specific tissues targeted by your compound, thereby identifying unexpected adverse effects and additional benefits, or for stratifying heterogeneous patient populations for clinical trials.
  • FFA turnover technique to complete the overview of your drug compound’s impact on whole-body insulin sensitivity and lipid metabolism.

Fact sheet

REFERENCES

Issandou M et al.
Eur J Pharmacol. 2009.
ico-link
Sulpice T. et al.
Endocrinology, 2009.
ico-link